Plasma cell-free RNA PD-L1 expression and survival with immune checkpoint inhibitor-based treatment in advanced non-small-cell lung cancer

被引：0
|
作者：
Walker, Paul R. [1 ]
Jayananda, Sriraksha [1 ]
Pasli, Melisa [1 ]
Muzaffar, Mahvish [1 ]
机构：
[1] East Carolina Univ, Brody Sch Med, Greenville, NC 27858 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21090
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Plasma cell-free RNA PD-L1 or Tissue PD-L1 Protein Expression and Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer
    Walker, Paul R.
    Jayananda, Sriraksha
    Pasli, Melisa
    Muzaffarl, Mahvish
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E17 - E17
  • [2] Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients
    Yang, Qiao
    Chen, Mingjing
    Gu, Jiaoyang
    Niu, Kai
    Zhao, Xianlan
    Zheng, Linpeng
    Xu, Zihan
    Yu, Yongxin
    Li, Feng
    Meng, Lingxin
    Chen, Zhengtang
    Zhuo, Wenlei
    Zhang, Luping
    Sun, Jianguo
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [3] Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
    Shen, Xuxia
    Li, Yuan
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1817 - 1818
  • [4] PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
    Aguiar, Pedro N., Jr.
    De Mello, Ramon Andrade
    Hall, Peter
    Tadokoro, Hakaru
    de Lima, Gilberto
    IMMUNOTHERAPY, 2017, 9 (06) : 499 - 506
  • [5] Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
    Shen, Xuxia
    Li, Yuan
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1817 - 1818
  • [6] The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression
    Ochi, Nobuaki
    Ichihara, Eiki
    Takigawa, Nagio
    Harada, Daijiro
    Inoue, Koji
    Shibayama, Takuo
    Hosokawa, Shinobu
    Kishino, Daizo
    Harita, Shingo
    Oda, Naohiro
    Hara, Naofumi
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    EUROPEAN JOURNAL OF CANCER, 2021, 149 : 73 - 81
  • [7] Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
    Tachibana, Yusuke
    Morimoto, Kenji
    Yamada, Tadaaki
    Kawachi, Hayato
    Tamiya, Motohiro
    Negi, Yoshiki
    Goto, Yasuhiro
    Nakao, Akira
    Shiotsu, Shinsuke
    Tanimura, Keiko
    Takeda, Takayuki
    Okada, Asuka
    Harada, Taishi
    Date, Koji
    Chihara, Yusuke
    Hasegawa, Isao
    Tamiya, Nobuyo
    Katayama, Yuki
    Nishioka, Naoya
    Iwasaku, Masahiro
    Tokuda, Shinsaku
    Kijima, Takashi
    Takayama, Koichi
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (05) : 538 - 546
  • [8] PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer
    Pennell, Nathan A.
    JAMA ONCOLOGY, 2016, 2 (05) : 569 - 570
  • [9] Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
    Li, Lijun
    Pu, Haihong
    Zhang, Xiaoxin
    Guo, Xiaotian
    Li, Guangrui
    Zhang, Minghui
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 209
  • [10] Targeting PD-L1 for non-small-cell lung cancer
    Feld, Emily
    Horn, Leora
    IMMUNOTHERAPY, 2016, 8 (06) : 747 - 758
12345